

Exploring the association of side-effects with depression in patients with chronic lymphocytic leukemia who have received treatment - an analysis of the Lymphoma Coalition's 2022 global patient survey

LYMPHOMA
COALITION

Abstract #842P

N. Bolanos Fernandez¹, S. Kalloger², A. Watson³, S. Sajkowski⁴, L. Warwick⁵
¹ Head Membership & Alliances, Lymphoma Coalition, Madrid, Spain, ² Research, Lymphoma Coalition, Mississauga, ON, Canada, ³ Research, Lymphoma Coalition - Head Office, Mississauga, Canada, ⁴ Research, Lymphoma Coalition, Mississauga, Canada, ⁵ Head Office, Lymphoma Coalition, Mississauga, Canada

Introduction

The Lymphoma Coalition (LC) supports over 90 patient organizations across 55+ countries, aiming to create a global community that advocates for patients living with lymphoma and CLL through evidence-based efforts, backed by patient experience data. Symptoms of depression are highly prevalent amongst patients with cancer. We sought to identify which treatment related side-effects were associated with an increased incidence of depression in patients with chronic lymphocytic leukemia (CLL).

Methods

Study Design
A global survey was deployed in 2022 to gather patient reported outcomes and patient reported experience measures from a cross-section of patients with lymphoma and CLL.

Respondents
The entire sample had a median age of 66 years with a range of 26-97 and 46% were female.

Statistical Analysis
The incidence of 32 side-effects were cross-tabulated with reports of depression amongst patients with CLL who received treatment.

Results

Of the 611 respondents who received treatment and disclosed whether they suffered from depressive symptoms, 21% (N = 131) reported experiencing depression.




Figure 1. Percentage increase of experienced side-effects for those with depression.

Figure 2. Experience of side-effects in full cohort.

Results cont

The side-effects listed in figure 2 were found to be significantly associated with increased reports of depression. No significant differences in age or biological sex were found.

Conclusion

The large breadth of side-effects (N = 23) that are associated with increased incidence of depression suggests that interventions to mitigate side-effects are likely to have unanticipated benefits for the health-related quality of life for patients with CLL. Implementation of assessment methods to ensure patients disclose all side effects and are provided with the appropriate supportive care will reduce comorbidities and yield improved outcomes for patients with CLL.

Conflict of interest/disclosure

The study was sponsored by AbbVie, BMS, Pharmacyclics and Roche. None of the authors benefited personally from the research.

Contact information

For further details on the LC 2022 GPS, Please scan the QR code or visit <https://lymphomacoalition.org/global-patient-survey/>
Copies of this poster obtained through QR are for personal use only and may no be reproduced without written permission of the authors. Please direct any queries to the research department at LC: steve@lymphomacoalition.org